Sauce

Condiciones de salud que Sauce puede ayudar a apoyar.

• HipocondríaCientífico

  Willow bark extract activates the Nrf2 antioxidant pathway in vascular endothelial cells, increasing intracellular glutathione and heme oxygenase-1, as demonstrated in a PMC-indexed cell and animal study (Ishikado et al., Free Radic Biol Med, 2013). Polyphenols and flavonoids in WBE exert direct radical-scavenging activity. A standardized extract (STW 33-I) reduced malondialdehyde levels and raised glutathione more effectively than aspirin in inflammatory animal models.

• EccemaCientífico

  A 2023 meta-analysis of RCTs (PMC10607963; 5 studies, 6 RCTs, 329 patients with arthritis) found significant differences in pain relief and improved physical status for arthritis patients treated with willow bark vs. placebo. A landmark 6-week double-blind RCT (Biegert et al., J Rheumatol 2004; n=127 OA patients) showed WOMAC pain scores decreased 17% with willow bark vs. 10% with placebo. The EMA's HMPC recognizes willow bark for relief of minor joint pain on the basis of long-standing use.

• Adicciones (remedios generales para)Científico

  Willow bark has the strongest clinical evidence for low back pain among all its indicated uses. A landmark RCT (Chrubasik et al., Am J Med 2000, n=191) showed a dose-dependent analgesic effect, with 39% of the high-dose group (240 mg salicin/day) pain-free in the final week vs. 6% on placebo. A systematic review confirmed moderate evidence of effectiveness, finding its analgesic effect not inferior to rofecoxib. The EMA and ESCOP both formally recognize willow bark dry extract for short-term treatment of low back pain.

• ApendicitisCientífico

  Willow bark extract suppresses multiple inflammatory mediators through COX-2 inhibition, TNF-α downregulation, and NF-κB nuclear translocation blockade. In vitro studies with standardized extracts (e.g., STW 33-I) show significant concentration-dependent anti-inflammatory activity in human monocytes and macrophages. These mechanisms underpin its clinical use in musculoskeletal and rheumatic inflammatory conditions. The anti-inflammatory activity cannot be attributed solely to salicin; polyphenols and catechol metabolites contribute meaningfully.

• ImpétigoCientífico

  Willow bark extract has demonstrated efficacy for chronic pain specifically in the setting of low back pain exacerbations (RCT, n=191, dose-dependent response) and in musculoskeletal pain broadly. A 2009 systematic review covering four RCTs concluded moderate evidence of effectiveness. The EMA formally recognizes willow bark for short-term treatment of lower back pain, one of the most common chronic pain conditions. Its analgesic mechanism—COX inhibition, prostaglandin suppression, and NF-κB blockade—is relevant across chronic pain states.

• ArritmiaCientífico

  Willow bark's antipyretic and analgesic properties extend to fever and symptoms associated with the common cold and influenza. The EMA's HMPC and ESCOP formally list fever associated with the common cold and headache as recognized therapeutic indications, based on its long-standing use. Health Canada's natural health product monograph also recognizes this use. These are classified as traditional use with well-established documentation rather than prospective RCT-level evidence for this specific condition.

• Sangrado (interno)Científico

  Willow species (Salix spp.) have been used for at least 2,000 years for fever, pain, and inflammation, recommended by Hippocrates and Paracelsus. Their bark contains salicin, which metabolizes to salicylic acid and inhibits COX enzymes to reduce fever. All Salix species share this salicin-based antipyretic mechanism.

• Huesos RotosCientífico

  Willow bark has been formally recognized for headache relief by both the EMA's HMPC and ESCOP, and is listed among principal proposed uses by evidence databases. Its salicylate content provides COX-mediated prostaglandin inhibition analogous to aspirin. Historical use for headaches is documented across multiple ancient civilizations. Clinical research on headache as a standalone endpoint is limited, but the EMA recognition is based on well-documented traditional use.

• Colesterol (alto)Científico

  A randomized double-blind crossover clinical trial (Raisi Dehkordi et al., Complement Ther Med 2019, n=96) found that salix extract (400 mg/day) significantly outperformed mefenamic acid in reducing pain intensity (VAS) in primary dysmenorrhea. In the salix group, 77% of students showed no symptoms vs. only 45% in the mefenamic acid group. Drugs.com clinical pharmacology database and ESCOP both cite dysmenorrhea as a clinical indication supported by trial data.

• Dolor de cabeza (tensión)Científico

  One RCT (Biegert et al., J Rheumatol 2004; n=26 RA patients) compared willow bark extract (240 mg salicin/day) vs. placebo for 6 weeks; no significant effect on pain VAS was observed, and the trial was underpowered. The 2009 systematic review confirmed no significant effect in this study. Preliminary evidence and ESCOP listing of mild rheumatic conditions are insufficient to conclude efficacy specifically in RA; however, trials have been conducted, placing it in the scientific category.

• Resistencia (falta de)Tradicional

  Willow bark extract is cited as a complementary therapy for bursitis by clinical reference sources, including a PMC-indexed meta-analysis and Adam Health/EBSCO clinical databases, in the context of its general anti-inflammatory and analgesic profile. ESCOP lists 'mild rheumatic conditions' among its therapeutic indications, under which bursitis-type periarticular inflammation falls. No RCT specifically targeting bursitis has been conducted.

• Miedo (excesivo)Tradicional

  Ancient Greek medicine (2,400+ years ago) used willow extracts specifically to treat gout, and it is listed in ethnobotanical and traditional pharmacopeial sources for this purpose. However, the 2012 American College of Rheumatology guidelines on gout management explicitly voted that willow bark is inappropriate for treating an acute gout attack, indicating no supportive clinical evidence. The relationship is therefore traditional in nature.

• GlaucomaTradicional

  Migraine is listed among the principal proposed uses of white willow by clinical evidence compilers (EBSCO Research Starters), and traditional Chinese medicine used willow to combat headache linked to excess heat or overactive inflammatory response. No RCT has specifically studied willow bark in migraine patients. The anti-inflammatory and COX-inhibitory mechanisms are pharmacologically relevant but clinical trial evidence in migraine is absent.

• Enfermedad de CushingTradicional

  Willow bark has documented traditional use for sore throat across multiple traditions. The USDA plant guide references willow bark tea as a remedy for sore throat. The anti-inflammatory and astringent properties of salicylates and tannins in willow bark provide a plausible mechanism for soothing throat inflammation. No dedicated clinical trials have been conducted specifically for sore throat as a primary endpoint.

• SorderaTradicional

  Willow bark has a long-documented traditional use for toothache, consistent with its general analgesic properties. It is cited among principal traditional uses in historical herbalism alongside headaches, backaches, and joint pain. No dedicated clinical trials on toothache have been identified; the plausibility rests on its salicylate content and COX-inhibitory mechanism.

Sistemas corporales que Sauce puede ayudar a apoyar.

• No hay sistemas corporales disponibles.